Cellectis Statistics
Total Valuation
Cellectis has a market cap or net worth of $108.22 million. The enterprise value is $49.17 million.
Important Dates
The last earnings date was Monday, May 12, 2025, after market close.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Cellectis has 100.16 million shares outstanding. The number of shares has increased by 58.85% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 100.16M |
| Shares Change (YoY) | +58.85% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 39.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.98 |
| Forward PS | 1.85 |
| PB Ratio | 0.93 |
| P/TBV Ratio | 0.93 |
| P/FCF Ratio | 5.30 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.90 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 2.41 |
Financial Position
The company has a current ratio of 1.67, with a Debt / Equity ratio of 0.50.
| Current Ratio | 1.67 |
| Quick Ratio | 1.64 |
| Debt / Equity | 0.50 |
| Debt / EBITDA | n/a |
| Debt / FCF | 2.83 |
| Interest Coverage | -7.09 |
Financial Efficiency
Return on equity (ROE) is -58.55% and return on invested capital (ROIC) is -17.92%.
| Return on Equity (ROE) | -58.55% |
| Return on Assets (ROA) | -9.19% |
| Return on Invested Capital (ROIC) | -17.92% |
| Return on Capital Employed (ROCE) | -26.22% |
| Revenue Per Employee | $246,613 |
| Profits Per Employee | -$272,667 |
| Employee Count | 222 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Cellectis has paid $262,000 in taxes.
| Income Tax | 262,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.65% in the last 52 weeks. The beta is 3.28, so Cellectis's price volatility has been higher than the market average.
| Beta (5Y) | 3.28 |
| 52-Week Price Change | -50.65% |
| 50-Day Moving Average | 1.37 |
| 200-Day Moving Average | 1.77 |
| Relative Strength Index (RSI) | 52.69 |
| Average Volume (20 Days) | 62,201 |
Short Selling Information
| Short Interest | 317,825 |
| Short Previous Month | 340,330 |
| Short % of Shares Out | 0.39% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.25 |
Income Statement
In the last 12 months, Cellectis had revenue of $54.75 million and -$60.53 million in losses. Loss per share was -$0.62.
| Revenue | 54.75M |
| Gross Profit | 54.75M |
| Operating Income | -52.84M |
| Pretax Income | -80.31M |
| Net Income | -60.53M |
| EBITDA | -41.27M |
| EBIT | -52.84M |
| Loss Per Share | -$0.62 |
Full Income StatementBalance Sheet
The company has $243.69 million in cash and $57.79 million in debt, giving a net cash position of $185.91 million or $1.86 per share.
| Cash & Cash Equivalents | 243.69M |
| Total Debt | 57.79M |
| Net Cash | 185.91M |
| Net Cash Per Share | $1.86 |
| Equity (Book Value) | 116.20M |
| Book Value Per Share | 1.16 |
| Working Capital | 109.26M |
Full Balance SheetCash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | 20.41M |
| FCF Per Share | $0.20 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -96.51% and -110.56%.
| Gross Margin | 100.00% |
| Operating Margin | -96.51% |
| Pretax Margin | -110.09% |
| Profit Margin | -110.56% |
| EBITDA Margin | -75.38% |
| EBIT Margin | -96.51% |
| FCF Margin | 37.27% |